

US Serial No. 09/737,908


Attorney Docket No. C059-03 US

AMENDMENTS TO THE CLAIMS

1-2 (Canceled)

RECEIVED
CENTRAL FAX CENTER
APR 17 2007


3. (Currently amended) A compound having the formula (I):



(I)

and salts thereof;

wherein R is:

wherein X and X' are independently C=O, C=S, C=NH, C=NR^X, S=O or SO₂;

wherein n is 0 or 1;

wherein R^X is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;wherein B is X''R^Y, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;wherein R^Y is hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;wherein A is H, NH₂, NHR^A, NR^AR^B, alkyl, alkenyl, alkynyl, alkoxy,


US Serial No. 09/737,908

Attorney Docket No. C059-03 US

aryloxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein R^A and R^B are independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;


wherein when n is 0, then A is additionally:



wherein each of R^{50} - R^{53} is independently C_1 - C_{15} alkyl;

alternatively, wherein B and A together form a 5-7 membered heterocyclic or heteroaryl ring;

wherein R^1 is



wherein X' and X'' are independently $C=O$, $C=S$, $C=NH$, $C=NR^X$, $S=O$ or SO_2 ;

wherein m is 0 or 1;

wherein R^X is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B' is $X'''R^Y$, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein R^Y is hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A' is unsubstituted alkyl, alkenyl, alkynyl, alkoxy, aryloxy; or alkyl wherein one or more hydrogen atoms is replaced by a substituent group selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl, oxo, guanidino, and formyl;

US Serial No. 09/737,908

Attorney Docket No. C059-03 US





provided that when B' is H then (X')_m-A' is other than

(a) -C(O)(C₁-C₁₆ unsubstituted alkyl)-NH₂;

(b) -C(O)(C₁-C₁₀ unsubstituted alkyl)-NHC(O)R^D, wherein R^D is -C₁-C₁₈ unsubstituted alkyl, or -C₁-C₁₈ selected substituted alkyl wherein one proton is replaced by a hydroxyl, carboxyl or C₁-C₃ alkoxy, or one to three protons is replaced by a halo ~~substituents~~ substituent;

(c) -C(O)C₁-C₁₈ unsubstituted alkyl;

(d) -C(O)C₄-C₁₈ unsubstituted alkenyl;



wherein R⁵⁴ is selected from C₁-C₁₇ unsubstituted alkyl or C₂-C₁₇ unsubstituted alkenyl; wherein R⁵⁵ is selected from hydroxyethyl, hydroxymethyl, mercaptomethyl, mercaptoethyl, methylthioethyl, 2-thienyl, 3-indolemthyl, phenyl optionally substituted with a group selected from halo, nitro, C₁-C₃-unsubstituted alkyl, hydroxy, C₁-C₃-unsubstituted alkoxy, C₁-C₃-unsubstituted alkylthio, carbamyl or C₁-C₃ unsubstituted alkylcarbamyl; or benzyl optionally substituted with a group selected from

US Serial No. 09/737,908

Attorney Docket No. C059-03 US


halo, nitro, C₁-C₃-unsubstituted alkyl, hydroxy, C₁-C₃-unsubstituted alkoxy, C₁-C₃-unsubstituted alkylthio, carbamyl or C₁-C₃ unsubstituted alkylcarbamyl; wherein t is 0 or 1 and wherein u is an integer from 1-3;

(f) -C(O)C₁-C₁₈ selected substituted alkyl wherein one proton is replaced by a hydroxyl, carboxyl or C₁-C₃ alkoxy, or one to three protons is replaced by a halo ~~substituents-substituent~~; and

(g) an amino protecting group; and


wherein when B' is H and m is 0, then A' is other than C₄-C₁₄ unsubstituted alkyl;

wherein R² is



wherein K and K' together form a C₃-C₇ cycloalkyl or heterocyclyl ring or a C₅-C₁₀ aryl or heteroaryl ring;

wherein J is hydrido, amino, NHR^J, NR^JR^K, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylamino, hydroxyl, thio, alkylthio, alkenylthio, sulfinyl, sulfonyl, azido, cyano, halo,



wherein each of R²⁴, R²⁵, and R²⁶ is independently alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or R²⁴ and R²⁵ together form a 5-8 membered heterocyclyl ring;

wherein R^J and R^K are independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; or


US Serial No. 09/737,908

Attorney Docket No. C059-03 US

alternatively, wherein J, together with R¹⁷, forms a 5-8 membered heterocyclyl or cycloalkyl ring; or


alternatively, wherein J, together with both R¹⁷ and R¹⁸, forms a 5-8 membered aryl, cycloalkyl, heterocyclyl or heteroaryl ring; and

wherein each of R¹⁷ and R¹⁸ is independently hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl or




; or

wherein R¹⁷ and R¹⁸ taken together can form a ketal, thioketal,



wherein each of R²² and R²³ is independently hydrido or alkyl.

4. (Previously presented) A compound having the formula (I):




and salts thereof;

wherein R is:

US Serial No. 09/737,908

Attorney Docket No. C059-03 US



wherein X and X' are independently C=O, C=S, C=NH, C=NR^X, S=O or SO₂;

wherein n is 0 or 1;

wherein R^X is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;


wherein B is X''R^Y, H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein R^Y is hydrido, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or hydroxyl;

wherein A is H, NH₂, NHR^A, NR^AR^B, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;

wherein R^A and R^B are independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;


wherein when n is 0, then A is additionally:



wherein each of R⁵⁰-R⁵³ is independently C₁-C₁₅ alkyl;

alternatively, wherein B and A together form a 5-7 membered heterocyclic or heteroaryl ring;

wherein R¹ is



wherein X' and X''' are independently C=O, C=S, C=NH, C=NR^{X'}, S=O or SO₂;

US Serial No. 09/737,908

Attorney Docket No. C059-03 US


wherein m is 0 or 1;

wherein R^X is alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, hydroxyl, alkoxy, carboxy or carboalkoxy;

wherein B' and A' together form a 5-7 membered heterocyclic or heteroaryl ring;


wherein $R^{A'}$ and $R^{B'}$ are independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl or carboalkoxy;

wherein R^2 is



wherein K and K' together form a C_3 - C_7 cycloalkyl or heterocyclyl ring or a C_5 - C_{10} aryl or heteroaryl ring;

wherein J is hydrido, amino, NHR^J , $NR^J R^K$, alkyl, alkenyl, alkynyl, alkoxy, aryloxy, aryl, heteroaryl, cycloalkyl, heterocyclyl, alkylamino, hydroxyl, thio, alkylthio, alkenylthio, sulfinyl, sulfonyl, azido, cyano, halo,



wherein each of R^{24} , R^{25} , and R^{26} is independently alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl; or R^{24} and R^{25} together form a 5-8 membered heterocyclyl ring;

wherein R^J and R^K are independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; or


alternatively, wherein J , together with R^{17} , forms a 5-8 membered heterocyclyl or cycloalkyl ring; or

US Serial No. 09/737,908

Attorney Docket No. C059-03 US


alternatively, wherein J, together with both R¹⁷ and R¹⁸, forms a 5-8 membered aryl, cycloalkyl, heterocyclyl or heteroaryl ring; and

wherein each of R¹⁷ and R¹⁸ is of hydrido, halo, hydroxyl, alkoxy, amino, thio, sulfinyl, sulfonyl or



; or

wherein R¹⁷ and R¹⁸ taken together can form a ketal, thioketal,




wherein each of R^{22} and R^{23} is independently hydrido or alkyl.

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

5. (Previously presented) The compound according to either of claims 3 or 4, wherein R is





wherein each of R³, R⁴, R⁵, and R⁶ is independently hydrido, alkyl, aryl, heterocyclyl or heteroaryl, and wherein R⁴⁴ alkyl, aryl, heterocyclyl or heteroaryl.

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

6. (Previously presented) The compound according to claim 5, wherein R is




wherein R^{4'} is alkyl, aryl-substituted alkyl, substituted phenyl, heteroaryl, heterocyclyl, optionally substituted (C₈-C₁₄)-straight chain alkyl or  SR⁷; wherein R⁷ is an alkyl group.

7. (Previously presented) The compound according to claim 6, wherein R is


US Serial No. 09/737,908

Attorney Docket No. C059-03 US



wherein X^3 is chloro or trifluoromethyl and wherein q is 0 or 1.

8. (Currently amended) The compound according to claim 3, wherein R^1 is:



wherein R^8 is a natural amino acid side chain or an amino acid side chain that is not naturally occurring;

wherein R^9 is hydrido, alkyl, aryl, heterocyclyl or heteroaryl;

wherein R^{12} is heterocyclyl, heteroaryl, aryl, or alkyl


provided that R^{12} is other than C_3 - C_{13} unsubstituted alkyl; and

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

wherein R^{13} is (C_1 - C_3 -alkyl) wherein one or more hydrogen atoms is replaced by a substituent group selected from acyl, amino, acylamino, acyloxy, carboalkoxy, carboxy, carboxyamido, cyano, halo, hydroxyl, nitro, thio, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, aryloxy, sulfinyl, sulfonyl, oxo, guanidino, and formyl.


9. (Previously presented) The compound according to claim 8, wherein R^1 is:



wherein R^8 is tryptophan side chain or lysine side chain;


wherein R^{12} is imidazolyl, N-methylimidazolyl, indolyl, quinoliny, benzyloxybenzyl, or benzylpiperidonylbenzyl.

10. (Previously presented) The compound according to either of claims 3



or 4, wherein J is hydrido, amino, azido or

wherein R^{17} and R^{18} taken together form a ketal,




or wherein R^{17} is hydroxyl when R^{18} is hydrido;

or wherein J, together with R^{17} , forms a heterocyclyl ring.



11. (Previously presented) The compound according to claim 10, wherein

US Serial No. 09/737,908



Attorney Docket No. C059-03 US

 R^2 is

or


wherein R^{17} and R^{18} taken together form a

or

, wherein R^{22} is H or alkyl; and wherein R^{19} is

hydrido, amino, azido or

12. (Previously presented) The compound according to claim 11, wherein

































 R^2 is

13. (Previously presented) The compound according to claim 3 wherein said compound is

Cpd #	R	R^1	R^2
37	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		































US Serial No. 09/737,908

Attorney Docket No. C059-03 US

38	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
39	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
40	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
41	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
42	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
43	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
44	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
45	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
46	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
47	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
48	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
49	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
50	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
51	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
52	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
54	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		

































US Serial No. 09/737,908

Attorney Docket No. C059-03 US

55	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
56	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
58	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
60	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
61	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
62	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
63	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
64	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
65	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
66	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
67	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
68	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
69	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
72	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
73	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

74	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
75	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
76	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
77	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$	$\text{NH}(\text{CH}_2)_2\text{OH}$	
78	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
79	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
80	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
81	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
82	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
83	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
84	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
85	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
86			
87	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
88	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
89	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

90	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
91	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
92	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
93	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
94	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
95	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
96	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
97	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
98	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
99	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
100	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
101			
102	$\text{NHCO}(\text{CH}_2)_{11}\text{CH}_3$		
103	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
104	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		





























US Serial No. 09/737,908

Attorney Docket No. C059-03 US

105	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
106	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
107	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
108	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
109	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
110	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
111	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
112	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
113	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
114	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
115	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
116	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
117	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
118	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
119	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

120	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
121	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
122	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
123	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
124	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
125	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
126	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
127	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
128	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
129	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
130	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
131	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
132	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
133	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		































US Serial No. 09/737,908

Attorney Docket No. C059-03 US

134	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
135	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
136	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
137	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
138	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
139	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
140	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
141	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
142	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
143	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
144	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
145	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
146	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
147	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
148	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

149	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
150	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
151	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
152	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
153	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
154	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
155	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
156	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
157	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
158	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
159	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
160	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
161	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
162	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
163	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		































US Serial No. 09/737,908

Attorney Docket No. C059-03 US

164	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
165	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
166	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
167	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
168	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
169	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
171	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
172	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
173	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
174	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
175	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
176	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
177	NH_2		
178	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
179	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		





























US Serial No. 09/737,908

Attorney Docket No. C059-03 US

180	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
181	$\text{NHCONH}(\text{CH}_2)_{10}\text{CH}_3$		
183	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
184	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
185	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
186	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
187	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
192	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
194	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
195	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
196	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
197	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
198	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
199	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
200	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		





























US Serial No. 09/737,908

Attorney Docket No. C059-03 US

201	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
202	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
203	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
204	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
205	$\text{NH}(\text{CH}_2)_8\text{CH}_3$		
206	$\text{NHCO}(\text{CH}_2)_8\text{CO}_2\text{Me}$		
207	$\text{NHCO}(\text{CH}_2)_6\text{CO}_2\text{Me}$		
208	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
209	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
210	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
211	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
212	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
213	$\text{NHCO}(\text{CH}_2)_6\text{NHBoc}$		
214	$\text{NHCO}(\text{CH}_2)_7\text{NHBoc}$		

































US Serial No. 09/737,908

Attorney Docket No. C059-03 US

215	$\text{NHCO}(\text{CH}_2)_{10}\text{NHBoc}$		
216	$\text{NHCO}(\text{CH}_2)_{11}\text{NHBoc}$		
217	$\text{NHCO}(\text{CH}_2)_{10}\text{NH}_2$		
218	$\text{NHCO}(\text{CH}_2)_{11}\text{NH}_2$		
219	$\text{NHCO}(\text{CH}_2)_8\text{CH}(\text{CH}_3)_2$		
220	$\text{NHCONH}(\text{CH}_2)_{11}\text{CH}_3$		
222	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
223	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
224	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
225	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
226	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
227	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
228	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
229	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		





































US Serial No. 09/737,908

Attorney Docket No. C059-03 US

230	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
231	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
232	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
233	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
234	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
235	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
236	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
237	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
238	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
239	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
240	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
241	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
242	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
243	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
244	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
245	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		





























US Serial No. 09/737,908

Attorney Docket No. C059-03 US

246			
247			
248			
249			
250			
251			
252	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
253	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
264			
265	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
266	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
267	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
268	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
269			





























US Serial No. 09/737,908

Attorney Docket No. C059-03 US

271	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
272	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
273	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
274	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
275	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
276	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
277	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
278	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
279	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
280	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
281	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
282	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
283	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
284	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

285	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
286	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
287	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
288	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
289	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
290	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
291	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
295	$\text{NHCO}(\text{CH}_2)_{11}\text{CH}_3$		
296	$\text{NHCO}(\text{CH}_2)_{10}\text{CH}_3$		
297	$\text{NHCO}(\text{CH}_2)_9\text{CH}_3$		
298	$\text{NHCONH}(\text{CH}_2)_7\text{CH}_3$		
299	$\text{NHCONH}(\text{CH}_2)_{10}\text{CH}_3$		
300	$\text{NHCONH}(\text{CH}_2)_{11}\text{CH}_3$		
301	$\text{NHCO}(\text{CH}_2)_{11}\text{CH}_3$		































US Serial No. 09/737,908

Attorney Docket No. C059-03 US

302	$\text{NHCO}(\text{CH}_2)_{10}\text{CH}_3$		
303	$\text{NHCO}(\text{CH}_2)_9\text{CH}_3$		
304	$\text{NHCONH}(\text{CH}_2)_7\text{CH}_3$		
305	$\text{NHCONH}(\text{CH}_2)_{10}\text{CH}_3$		
306	$\text{NHCONH}(\text{CH}_2)_{11}\text{CH}_3$		
307	$\text{NHCO}(\text{CH}_2)_9\text{CH}_3$		
308	$\text{NHCO}(\text{CH}_2)_{10}\text{CH}_3$		
309	$\text{NHCO}(\text{CH}_2)_{10}\text{CH}_3$		
310	$\text{NHCO}(\text{CH}_2)_9\text{CH}_3$		
311	$\text{NHCONH}(\text{CH}_2)_7\text{CH}_3$		
315	$\text{NHCONH}(\text{CH}_2)_7\text{CH}_3$		
316	$\text{NHCONH}(\text{CH}_2)_7\text{CH}_3$		
317	$\text{NHCONH}(\text{CH}_2)_7\text{CH}_3$		
318	$\text{NHCO}(\text{CH}_2)_9\text{CH}_3$		

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

319	$\text{NHCO}(\text{CH}_2)_9\text{CH}_3$		
320	$\text{NHCO}(\text{CH}_2)_{11}\text{CH}_3$		
321	$\text{NHCO}(\text{CH}_2)_{11}\text{CH}_3$		
322	$\text{NHCO}(\text{CH}_2)_{11}\text{CH}_3$		
323	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
324	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
325	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
326	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
327	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
328	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
329	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
330	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
331	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
332	$\text{NHCO}(\text{CH}_2)_{10}\text{CH}_3$		
333	$\text{NHCO}(\text{CH}_2)_{10}\text{CH}_3$		

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

334	$\text{NHCO}(\text{CH}_2)_{10}\text{CH}_3$		
335	$\text{NHCONH}(\text{CH}_2)_{11}\text{CH}_3$		
336	$\text{NHCONH}(\text{CH}_2)_{11}\text{CH}_3$		
337	$\text{NHCONH}(\text{CH}_2)_{11}\text{CH}_3$		
338	$\text{NHCO}(\text{CH}_2)_{12}\text{CH}_3$		
339	$\text{NHCO}(\text{CH}_2)_{12}\text{CH}_3$		
340	$\text{NHCO}(\text{CH}_2)_{12}\text{CH}_3$		
341	$\text{NHCO}(\text{CH}_2)_{12}\text{CH}_3$		
345	$\text{NHCO}(\text{CH}_2)_{12}\text{CH}_3$		
346	$\text{NHCO}(\text{CH}_2)_{12}\text{CH}_3$		
347	$\text{NHCO}(\text{CH}_2)_7\text{CH}_3$		
348	$\text{NHCO}(\text{CH}_2)_7\text{CH}_3$		
349	$\text{NHCO}(\text{CH}_2)_7\text{CH}_3$		
350			
351	$\text{NHCO}(\text{CH}_2)_{11}\text{CH}_3$		

































US Serial No. 09/737,908

Attorney Docket No. C059-03 US

352	$\text{NHCONH}(\text{CH}_2)_{10}\text{CH}_3$		
355	$\text{NHCONH}(\text{CH}_2)_{10}\text{CH}_3$		
356	$\text{NHCONH}(\text{CH}_2)_{10}\text{CH}_3$		
358	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
359	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
360	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
361	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
362	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
363	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
364	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
365	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
366	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
367	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
368	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
369	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
370	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		



























US Serial No. 09/737,908

Attorney Docket No. C059-03 US

371	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
372	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
373	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
374	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
375	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
376	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
377	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
378	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
379	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
380	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
381	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
382	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
383	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
384	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
385	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
386	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		



















US Serial No. 09/737,908

Attorney Docket No. C059-03 US

387	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
388	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
389	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
390	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
391	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
392	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
393	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
394	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
395	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
398	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
399	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
400	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
401	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		

US Serial No. 09/737,908































Attorney Docket No. C059-03 US

402	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
403	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
404	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
405	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
406	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
407	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
408	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
409	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		
410	$\text{NHCO}(\text{CH}_2)_8\text{CH}_3$		

14. (Original) The compound according to claim 13 wherein the compound is

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

Cpd #	R	R ¹	R ²
45	NHCO(CH ₂) ₈ CH ₃		
54	NHCO(CH ₂) ₈ CH ₃		
76	NHCO(CH ₂) ₈ CH ₃		
81	NHCO(CH ₂) ₈ CH ₃		
85	NHCO(CH ₂) ₈ CH ₃		
102	NHCO(CH ₂) ₁₁ CH ₃		
209	NHCO(CH ₂) ₈ CH ₃		
212	NHCO(CH ₂) ₈ CH ₃		
253	NHCO(CH ₂) ₈ CH ₃		
282	NHCO(CH ₂) ₈ CH ₃		
285	NHCO(CH ₂) ₈ CH ₃		
319	NHCO(CH ₂) ₉ CH ₃		
322	NHCO(CH ₂) ₁₁ CH ₃		
333	NHCO(CH ₂) ₁₀ CH ₃		
334	NHCO(CH ₂) ₁₀ CH ₃		

US Serial No. 09/737,908

Attorney Docket No. C059-03 US


Cpd #	R	R ¹	R ²
335	NHCONH(CH ₂) ₁₁ CH ₃		
336	NHCONH(CH ₂) ₁₁ CH ₃		
355	NHCONH(CH ₂) ₁₀ CH ₃		

15. (Previously presented) A compound of formula (I) according to claim 3, wherein R is NHCO-[(C₆-C₁₄)-alkyl]-CH₃, and R¹ and R² are selected from:

R ¹	R ²


US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/731,908

Attorney Docket No. C059-03 US




US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/737,908

Attorney Docket No. C059-03 US




US Serial No. 09/737.908

Attorney Docket No. C059-03 US





















US Serial No. 09/737,908

Attorney Docket No. C059-03 US



US Serial No. 09/737,908

Attorney Docket No. C059-03 US

16. (Original) The compound according to claim 15, wherein R is $\text{NHCO}-[(\text{CH}_2)_{6-14}]-\text{CH}_3$.

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

17. (Previously presented) A pharmaceutical composition comprising the compound according to either-one of claims 3 or 4 and a pharmaceutically acceptable carrier.

18. (Original) A method of treating a bacterial infection in a subject, comprising the step of administering the pharmaceutical composition according to claim 17 to a subject in need thereof for a time and under conditions effective to ameliorate said bacterial infection

19. (Original) The method according to claim 18, wherein said subject is a human, an animal, a cell culture or a plant.

20. (Original) The method according to claim 18, wherein said bacterial infection is caused by a gram-positive bacteria.

21. (Previously presented) The method according to claim 20, wherein said bacteria is an antibiotic-resistant bacteria that is resistant to an antibiotic that is not included within the scope of Formula (I).

22. (Original) The method according to claim 21, wherein said antibiotic-resistant bacteria are resistant to vancomycin, methicillin, glycopeptide antibiotics, penicillin or daptomycin.

23. (Previously presented) The method according to claim 18, further comprising the step of co-administering more than one compound of Formula (I) according to either of claims 3 or 4 to a subject in need thereof.

24. (Previously presented) The method according to claim 18, further comprising the step of co-administering a second antimicrobial agent wherein said second antimicrobial agent is not included within the scope of Formula (I).

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

25. (Previously presented) The method according to claim 24, wherein said antimicrobial agent is penicillins, carbapenems, cephalosporins, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, fusidate sodium, lincomycin, clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramins, anti-folate agents, trimethoprim, pyrimethamine, nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide, para-aminosalicylic acid (PAS), cycloserine, capreomycin, ethionamide, prothionamide, thiacetazone, viomycin, everninomicin, glycopeptide, glycylicline, ketolides, oxazolidinones, imipenen, amikacin, netilmicin, fosfomycin, gentamicin, ceftriaxone, ZIRACIN (56-deacetyl-57-demethyl-45-O-de(2-methyl-1-oxopropyl)-12-O-(2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-alpha-L-arabino-hexopyranosyl)flambamycin), LY333328 (oritavancin), linezolid (N-[(5S)-3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide), SYNERCID (dalbopristin-quinupristin), aztreonam (2-[(Z)-[1-(2-amino-4-thiazolyl)-2-[(2S,3S)-2-methyl-4-oxo-1-sulfo-3-azetidiny] amino]-2-oxoethylidene]amino]oxy]-2-methylpropanoic acid), metronidazole (2-methyl-5-nitro-1H-imidazole-1-ethanol), epiroprim (5-[[3,5-diethoxy-4-(1H-pyrrol-1-yl)phenyl]methyl]-2,4-pyrimidinediamine), OCA-983 (1-[[[(2S)-2-amino-3-methyl-1-oxobutyl]amino]-2,5-anhydro-3-S-[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]-1,4-dideoxy-3-thio-D-threo-pentitol), GV-143253 (trinem), sanfetrinem ((1S, 5S, 8aS, 8bR)-1, 2, 5, 6, 7, 8, 8a, 8b-octahydro-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-azeto[2,1-a]isoindole-4-carboxylic acid), CS-834 ((4R, 5S, 6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[[(3R)-5-oxo-3-pyrrolidinyl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester), biapenem (6-[[[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6, 7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium inner salt), KA 159 (stipiamide), dynemicin A ((1S,4R,4aR,14S,14aS,18Z)-1,4,7,12,13, 14-hexahydro-6,8,11-trihydroxy-3-methoxy-1-methyl-7,12-dioxo-4a,14a-epoxy-4,14-[3]hexene[1,5]diynonaphtho[2,3-c]phenanthridine-2-carboxylic acid), DX8739 ((4R,5S,6S)-3-[(3S,5S)-5-[[4-[(2S)-5-amino-2-hydroxy-1-

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

oxopentyl]-1-piperazinyl]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), DU 6681 ((4R,5S,6S)-3-[[[(6S)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-6-yl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), cefluprenam ((2E)-N-(2-amino-2-oxoethyl)-3-[(6R,7R)-7-[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)](fluoromethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]-N-ethyl-N-methyl-2-propen-1-aminium inner salt), ER 35786 ((4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinylmethyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrochloride), cefoselis ((6R,7R)-7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[[2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid), sanfetrinem ccelexetil ((1S,5S,8aS,8bR)-1,2,5,6,7,8,8a,8b-octahydro-1-[(1R)-1-hydroxyethyl]-5-methoxy-2-oxo-azeto[2,1-a]isoindole-4-carboxylic acid 1-[(cyclohexyloxy)carbonyl]oxy]ethyl ester), cefpirome (1-[[[(6R,7R)-7-[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7-dihydro-5H-cyclopenta[b]pyridinium inner salt), HMR-3647 (3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]-erythromycin), RU-59863 (C-7 catechol substituted cephalosporin), KP 736 ((6R,7R)-7-[[[(2Z)-(2-amino-4-thiazolyl)][(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy]imino]acetyl]amino]-8-oxo-3-[(1,2,3-thiadiazol-5-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid disodium salt), Rifalazil (1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-[4-(2-methylpropyl)-1-piperazinyl]-1-oxo-rifamycin VIII, MEN 10700 ((5R,6S)-3-[[[(2-amino-2-oxoethyl)methylamino]methyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), lenapenem ((4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(1R)-1-hydroxy-3-(methylamino)propyl]-3-pyrrolidinyl]thio]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), BO 2502A ((4R,5S,6S)-3-[(2S,3'S,4S)-[2,3'-bipyrrolidin]-4-ylthio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

carboxylic acid), NE-1530 (3'-sialyllacto-N-neotetraose), K130 (5-[[4-[3-[[4-[(4-aminophenyl)sulfonyl]phenyl]amino]propoxy]-3,5-dimethoxyphenyl] methyl]-2,4-pyrimidinediamine), PD 138312 ((R)- 7-[3-(1-amino-1-methylethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid), PD 140248 (7-[(3R)-3-[(1S)-1-aminoethyl]-1-pyrrolidinyl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid), CP 111905 (5-deoxy-5-[[[(2E)-3-[3-hydroxy-4-(2-propenyloxy)phenyl]-2-methyl-1-oxo-2-propenyl]amino]-1,2-O-methylenc-D-neo-inositol), sulopenem ((5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid), ritipenam acoxyl ((5R,6R)-3-[[[(aminocarbonyl)oxy]methyl]-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (acetyloxy)methyl ester), RO-65-5788 ((6R,7R)- 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(hydroxyimino)acetyl]amino]-3-[(E)-[(3'R)-1'-[[[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl]-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monosodium salt), Sch-40832 (N-[[48-[1-[[2,6-dideoxy-3-O-(2,6-dideoxy-D-arabino-hexopyranosyl)-D-arabino-hexopyranosyl]oxy]ethyl]-15-ethylidene-1,3a,4,5,10,11,12,13,14,15,19,20,21,22,28,29,41,42-octadecahydro-41-hydroxy-12,45-bis(1-hydroxyethyl)-1-(hydroxymethyl)-22-(1-hydroxy-1-methylpropyl)-36-methyl-51,54,57-tris(methylene)-3-(methylthio)-10,13,20,27,38,49,52,55,58-nonaoxo-18H,27H-5a,29-(iminoethaniminoethaniminoethaniminoethanimino[7,2]quinolinomethanoxy methano)-9,6:19,16:26,23:33,30-tetranitrilo-16H,33aH-imidazo[1',5':1,6]pyrido [3,2-m][1,11,17,24,4,7,20,27]tetrathiatetraazacyclotriacontin-1-yl]carbonyl]-2,3-didehydroalanyl-2,3-didehydroalanine methyl ester stereoisomer), micacocidin A ((OC-6-26-A)-[(4S)-2-[(2S)-2-[(2R,4R)-2-[(4R)-4,5-dihydro-2-[2-(hydroxy-.kappa.O)-6-pentylphenyl]-4-thiazolyl-.kappa.N3]-3-methyl-4-thiazolidinyl-.kappa.N3]-2-(hydroxy-.kappa.O)-1,1-dimethylethyl]-4,5-dihydro-4-methyl-4-thiazolecarboxylato(2-)-.kappa.N3, .kappa.O4]-Zinc), SR-15402 ((1S,5S,8aS,8bR)-1,2,5,6,7,8,8a,8b-octahydro-1-[(1R)-1-hydroxyethyl]-2-oxo-5-[(3S)-3-pyrrolidinylthio]-azeto[2,1-a]isoindole-4-carboxylic acid), TOC 39 (1-(2-amino-2-oxoethyl)-4-[[[(1E)-2-[(6R,7R)-7-[[[(2Z)-(2-amino-4-thiazolyl)

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

(hydroxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]ethenyl]thio]-pyridinium inner salt), carumonam ([[(Z)-[2-[[[(2S,3S)-2-[[[(aminocarbonyl)oxy]methyl]-4-oxo-1-sulfo-3-azetidiny]amino]-1-(2-amino-4-thiazolyl)-2-oxoethylidene]amino]oxy]-acetic acid), cefozopran (1-[[[(6R,7R)-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(methoxy imino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-imidazo[1,2-b]pyridazinium inner salt), cefetamet pivoxil ((6R,7R)-7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxy imino)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester), and T 3811 (des-F(6)-quinolone).

26. (Previously presented) The method according to claim 24, wherein said antimicrobial agent is selected from the group consisting of imipenen, amikacin, netilmicin, fosfomycin, gentamicin, ceftriaxone, teicoplanin, ZIRACIN, LY333328, CL331022, HMR3647, linezolid, SYNERCID, aztreonam and metronidazole.


27. (Currently amended) The method according to claim 19, wherein said subject is selected from a human or an animal.

28. (Original) The method according to claim 27, wherein said subject is a human.



US Serial No. 09/737,908

Attorney Docket No. C059-03 US

29. (Original) The compound of claim 3 having the formula (III):



wherein R^{15} is hydrido or a carbamate amino protecting group,; wherein R^{16} is














and wherein, R^{20} is an amino acid side chain.

30. (Original) The compound according to claim 29 selected from:

Compound #	R^{16}
45	













US Serial No. 09/737,908

Attorney Docket No. C059-03 US

Compound #	R ¹⁶
54	
79	
80	
81	
82	
84	
139	
158	
146	
212	
85	













US Serial No. 09/737,908

Attorney Docket No. C059-03 US

Compound #	R ¹⁶
174	
78	
150	
130	
138	
168	
274	
317	
280	
275	
283	
285	

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

Compound #	R ¹⁶
50	
38	
115	
105	
76	
147	
164	
210	
107	
111	
103	
253	

US Serial No. 09/737,908

Attorney Docket No. C059-03 US

Compound #	R ¹⁶
227	
372	
386	

31. Canceled

32. (Previously presented) The compound according to claim 4 wherein said compound is

189	NHCO(CH ₂) ₈ CH ₃		
-----	---	--	--

33. (Previously presented) A compound of formula (I) according to claim 4, wherein R is NHCO-[(C₆-C₁₄)-alkyl]-CH₃, and R¹ and R² are:

R ¹	R ²